+476.2%
STX vs MRNA
-3.2%
+479.4%
-57.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | -3.4% | +0.4% | -2.9% |
| 7D | +14.6% | -12.1% | +26.7% | +15.2% |
| 30D | -26.0% | -1.3% | -24.7% | -25.9% |
| 3M | -42.6% | +250.9% | -293.6% | -47.1% |
| 6M | -35.3% | +343.0% | -378.3% | -43.5% |
| YTD | +92.5% | +657.4% | -565.0% | +52.3% |
| 1Y | +102.4% | +794.9% | -692.5% | +55.5% |
| 3Y | +673.8% | +218.1% | +455.7% | +549.1% |
| All | +476.2% | -3.2% | +479.4% | +441.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling